MindAffect MindAffect is a Dutch neurotechnology company developing objective hearing and vision assessments from automatic brain responses. Its Sofi Hearing Assessment System uses an EEG headset and its Rapid-CAEP cortical-response analysis technology to estimate frequency-specific hearing thresholds without requiring patients to speak, press a button or follow behavioral testing instructions. The approach is intended for children and people with communication or cognitive difficulties. MindAffect also develops KinderCap, KinderGaze and GLAM vision-assessment concepts using controlled visual stimuli, EEG and, in some designs, eye tracking. The company spun out of Radboud University’s Donders Institute with NLC in 2017. Its current site states that Sofi and Rapid-CAEP remain under development and are not certified for clinical diagnostic use. MindAffect reports FDA Breakthrough Device designation for Sofi in January 2026; this is a development pathway designation, not FDA marketing clearance.
Founded 2017
Peter Desain Founder and BCI Researcher (published history; current operating title unverified) Simon Bambach Supervisory Board Member (appointed July 2022; current status unverified) Tanja Claasen Supervisory Board Member (appointed July 2022; current status unverified)
SHOW MORE
$— 2021-09-06 Oost NL €400K Unknown date 0 participations €915K Unknown date 0 participations €500K Unknown date 0 participations €1M Unknown date NLC Health Ventures
SHOW MORE
team@apexlogos.ai · yesterday
Investor, fund and grant provenance, 8 October 2026. The April 2024 issuer/NLC release specifically names NLC Health Impact Fund as participant; the existing manager is NLC Health Ventures / Investor 1769 and fund 80SBQ21XYJPE4V0MTSH9GTY7S6WH5R8J. No ticket, lead status, exact legal subscriber or 2025 fund allocation is inferred. July 2025 issuer release thanks NLC Health Ventures, Wasteland, Barco Limpo and private investors, but does not specify which provided the incremental equity; no named new participation is inferred for the extension; the latter two firms remain queued for full identity/profile research, not bare stubs. The 2021 issue specifically names Oost NL, NLC-network investors and MSB Isala; network participation does not by itself prove a manager cheque. Other own news refers to Eurostars, MIT partnership, GLAM and a shared KinderGaze grant with Purple Gaze. Consortium grant totals are not solely company cash; exact grant dates/allocations and legal grantors remain queued, with no equity parts invented. Sources: https://www.nlc.health/insight/ai-healthtech-start-up-mindaffect-raises-eu1-1-million-to-transform-hearing-diagnostics ; https://www.mindaffect.nl/_files/ugd/8efee4_3633cb4f55b441c58fc22f7ad667d637.pdf ; https://www.mindaffect.nl/news SHOW MORE
team@apexlogos.ai · yesterday
team@apexlogos.ai · yesterday
Published roster scope, 8 October 2026. Thirteen current staff and three advisers are copied from the live visible company directory; exact personal links are issuer-linked. Three supervisory-board appointments come from the original 26 July 2022 issuer release and are explicitly qualified current status unverified. Outside job captions are historical context rather than MindAffect employment. Peter Desain is included as founder and originating BCI researcher, supported by the company history and his 2024 original scientific disclosure; no current operating rank or Scientific Advisor title has been guessed. Team CMS import and publish dates are not appointment dates. Sources: https://www.mindaffect.nl/about ; https://www.mindaffect.nl/_files/ugd/8efee4_189893709e3344528f891e619e184bb5.pdf ; https://pubmed.ncbi.nlm.nih.gov/39776784/ SHOW MORE
team@apexlogos.ai · yesterday
Clinical and product status, 8 October 2026. Own current solutions page explicitly states Sofi and Rapid-CAEP are under development and not yet certified for clinical diagnostic use. January 2026 issuer release reports FDA Breakthrough Device designation and a target 510(k) milestone in Q2 2027; it does not establish marketing authorization. Development studies, pre-clinical usability testing, award wins and projected launch dates are not approval. Earlier Aurora name is retained as historical product context; current company uses Sofi. Sources: https://www.mindaffect.nl/solutions ; https://www.mindaffect.nl/_files/ugd/8efee4_d139c41cbee6478186e80db8470ef0dc.pdf SHOW MORE
